The risk may arise when a representative of one company discloses an internal policy approach to managing MFN, particularly if that approach is likely to be reflected in a future submission or engagement with government.
A 'meeting of minds' and the risk of not being able to 'unknow' information
February 9, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News -
Pharmac aims to pivot toward faster process and broader value framework
August 17, 2026 - -
The 'Dispatched' Podcast - Series 5. Ep.28
August 16, 2026 - - Podcast -
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 - - Australian Biotech -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech

